Aoki H, Ohshima Y, Tanaka M, Okazaki O, Hakusui H
Exploratory Research Laboratories I, Daiichi Pharmaceutical Co. Ltd., Tokyo, Japan.
J Chromatogr B Biomed Appl. 1994 Oct 14;660(2):365-74. doi: 10.1016/0378-4347(94)00319-x.
A sensitive and specific HPLC method for the determination of DU-6859a (I), a fluoroquinolone antibacterial agent, in human serum and urine was developed. Compound I and the internal standard extracted from serum and urine by means of a Bond Elut C8 LRC cartridge showed recoveries of 96%. The extracts were chromatographed on a reversed-phase column with photolysis-fluorescence detection. This unique detection method was 42.5 times more sensitive than intrinsic fluorescence detection, the limits of detection being in 3.43 ng/ml for serum and 4.35 ng/ml for urine. In addition, I was stable in serum and urine for at least 1 month at -20 degrees C. The proposed method was sensitive and selective enough to apply to pharmacokinetic studies of I in humans after a single oral dose of 100 mg.
建立了一种灵敏且特异的高效液相色谱法，用于测定人血清和尿液中氟喹诺酮类抗菌剂DU - 6859a（I）。通过Bond Elut C8 LRC柱从血清和尿液中提取的化合物I和内标物的回收率为96%。提取物在反相柱上进行色谱分离，并采用光解 - 荧光检测。这种独特的检测方法比固有荧光检测灵敏42.5倍，血清的检测限为3.43 ng/ml，尿液的检测限为4.35 ng/ml。此外，I在血清和尿液中于-20℃下至少可稳定1个月。所提出的方法灵敏且具选择性，足以应用于单次口服100 mg I后在人体中的药代动力学研究。
